HSN: 356

NAME: SPIRONOLACTONE

CAS-RN: 52-01-7

DATE: 20180416

Risk Values - Summary Table

Summary Risk Table for:SPIRONOLACTONE
Risk Value Parameter OrganizationATSDRHealth CanadaIARCIPCSIPRVITER PRNSF IntlRIVMTCEQU.S.EPA
Oral: Non-Cancer
--
--
--
--
--
--
--
--
--
--
Oral: Cancer
--
--
green check
--
--
--
--
--
--
--
Inhalation: Non-Cancer
--
--
--
--
--
--
--
--
--
--
Inhalation: Cancer
--
--
green check
--
--
--
--
--
--
--
green check = Chemical evaluated and ITER data online.


Noncancer Oral Risk Values Table:

ITER Noncancer Oral Risk Table for: SPIRONOLACTONE
Risk Value Parameter OrganizationATSDRHealth CanadaIARCIPCSIPRVITER PRNSF IntlRIVMTCEQU.S.EPA
Risk Value Name
--
--
--
--
--
--
--
--
--
--
Risk Value*
--
--
--
--
--
--
--
--
--
--
Year
--
--
--
--
--
--
--
--
--
--
Base(Experimental)*
--
--
--
--
--
--
--
--
--
--
Basis(Adjusted)*
--
--
--
--
--
--
--
--
--
--
Uncertainty Factor
--
--
--
--
--
--
--
--
--
--
Critical Organ or Effect
--
--
--
--
--
--
--
--
--
--
Species
--
--
--
--
--
--
--
--
--
--
Study
--
--
--
--
--
--
--
--
--
--
Biomonitoring Blood
--
--
--
--
--
--
--
--
--
--
Biomonitoring Urine
--
--
--
--
--
--
--
--
--
--
View Specific:
--
--
--
--
--
--
--
--
--
--
*In mg/kg body weight per day, unless otherwise specified.

Noncancer Oral Specifics:


Cancer Oral Risk Values Table:

ITER Cancer Oral Risk Table for: SPIRONOLACTONE
Risk Value Parameter OrganizationATSDRHealth CanadaIARCIPCSIPRVITER PRNSF IntlRIVMTCEQU.S.EPA
Risk Value Name
--
--
NA
--
--
--
--
--
--
--
Risk Value*
--
--
NA
--
--
--
--
--
--
--
Year
--
--
2001
--
--
--
--
--
--
--
Classification
--
--
3
--
--
--
--
--
--
--
Target Organ
--
--
NA
--
--
--
--
--
--
--
Species
--
--
NA
--
--
--
--
--
--
--
Study
--
--
NA
--
--
--
--
--
--
--
Biomonitoring Blood
--
--
--
--
--
--
--
--
--
--
Biomonitoring Urine
--
--
--
--
--
--
--
--
--
--
View Specific:
--
--
Click here
--
--
--
--
--
--
--
*In mg/kg body weight per day, unless otherwise specified.


Cancer Oral Synopsis:

IARC has evaluated the carcinogenicity data for spironolactone. IARC has classified spironolactone as not classifiable as to its carcinogenicity to humans (Group 3). There is inadequate evidence in humans and limited evidence in experimental animals for the carcinogenicity of spironolactone. The IARC evaluation considers the evidence of carcinogenicity in humans and experimental animals, as well as other data relevant to the evaluation of carcinogenicity and its mechanisms. IARC does not generally develop risk values or other estimates of potency.

Cancer Oral Specifics:

IARC

PEER:
Each IARC evaluation is developed by an international working group of experts, which meets to discuss and finalize the monograph text and to formulate the evaluations. Working Group members are chosen on the basis of their knowledge and experience, with due regard given to avoid situations where financial or other interests might affect the outcome of their work. The members of a Working Group are invited to serve in their individual capacities as scientists, and not as representatives of their governments or of any organization with which they are affiliated. Representatives of national and international agencies are also invited to the meetings, and others may attend as observers.

MOREI:
International Agency for Research on Cancer (IARC) Monographs. Some Thyrotropic Agents. 2001. Volume 79, page 333. Summaries &; Evaluations available at http://monographs.iarc.fr/ENG/Monographs/vol79/index.php

Additional information about the IARC Monographs (including ordering information and links to other Monographs) can be found at http://monographs.iarc.fr/


Noncancer Inhalation Risk Values Table:

ITER Noncancer Inhalation Risk Table for: SPIRONOLACTONE
Risk Value Parameter OrganizationATSDRHealth CanadaIARCIPCSIPRVITER PRNSF IntlRIVMTCEQU.S.EPA
Risk Value Name
--
--
--
--
--
--
--
--
--
--
Risk Value*
--
--
--
--
--
--
--
--
--
--
Year
--
--
--
--
--
--
--
--
--
--
Base(Experimental)*
--
--
--
--
--
--
--
--
--
--
Basis(Adjusted)*
--
--
--
--
--
--
--
--
--
--
Uncertainty Factor
--
--
--
--
--
--
--
--
--
--
Critical Organ or Effect
--
--
--
--
--
--
--
--
--
--
Species
--
--
--
--
--
--
--
--
--
--
Study
--
--
--
--
--
--
--
--
--
--
Biomonitoring Blood
--
--
--
--
--
--
--
--
--
--
Biomonitoring Urine
--
--
--
--
--
--
--
--
--
--
View Specific:
--
--
--
--
--
--
--
--
--
--
*In mg/kg body weight per day, unless otherwise specified.

Noncancer Inhalation Specifics:


Cancer Inhalation Risk Values Table:

ITER Cancer Inhalation Risk Table for: SPIRONOLACTONE
Risk Value Parameter OrganizationATSDRHealth CanadaIARCIPCSIPRVITER PRNSF IntlRIVMTCEQU.S.EPA
Risk Value Name
--
--
NA
--
--
--
--
--
--
--
Risk Value*
--
--
NA
--
--
--
--
--
--
--
Year
--
--
2001
--
--
--
--
--
--
--
Classification
--
--
3
--
--
--
--
--
--
--
Target Organ
--
--
NA
--
--
--
--
--
--
--
Species
--
--
NA
--
--
--
--
--
--
--
Study
--
--
NA
--
--
--
--
--
--
--
Biomonitoring Blood
--
--
--
--
--
--
--
--
--
--
Biomonitoring Urine
--
--
--
--
--
--
--
--
--
--
View Specific:
--
--
Click here
--
--
--
--
--
--
--
*In mg/kg body weight per day, unless otherwise specified.


Cancer Inhalation Synopsis:

IARC has evaluated the carcinogenicity data for spironolactone. IARC has classified spironolactone as not classifiable as to its carcinogenicity to humans (Group 3). There is inadequate evidence in humans and limited evidence in experimental animals for the carcinogenicity of spironolactone. The IARC evaluation considers the evidence of carcinogenicity in humans and experimental animals, as well as other data relevant to the evaluation of carcinogenicity and its mechanisms. IARC does not generally develop risk values or other estimates of potency.

Cancer Inhalation Specifics:

IARC

PEER:
Each IARC evaluation is developed by an international working group of experts, which meets to discuss and finalize the monograph text and to formulate the evaluations. Working Group members are chosen on the basis of their knowledge and experience, with due regard given to avoid situations where financial or other interests might affect the outcome of their work. The members of a Working Group are invited to serve in their individual capacities as scientists, and not as representatives of their governments or of any organization with which they are affiliated. Representatives of national and international agencies are also invited to the meetings, and others may attend as observers.

MOREI:
International Agency for Research on Cancer (IARC) Monographs. Some Thyrotropic Agents. 2001. Volume 79, page 333. Summaries &; Evaluations available at http://monographs.iarc.fr/ENG/Monographs/vol79/index.php

Additional information about the IARC Monographs (including ordering information and links to other Monographs) can be found at http://monographs.iarc.fr/

NO Revision History: